Nitisinone
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hereditary Tyrosinemia, Type I
Conditions
Hereditary Tyrosinemia, Type I
Trial Timeline
Sep 1, 2013 → Sep 30, 2019
NCT ID
NCT02320084About Nitisinone
Nitisinone is a pre-clinical stage product being developed by Swedish Orphan Biovitrum for Hereditary Tyrosinemia, Type I. The current trial status is completed. This product is registered under clinical trial identifier NCT02320084. Target conditions include Hereditary Tyrosinemia, Type I.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06227429 | Pre-clinical | Withdrawn |
| NCT02323529 | Phase 3 | Completed |
| NCT02320084 | Pre-clinical | Completed |
| NCT01734889 | Phase 1 | Completed |
Competing Products
20 competing products in Hereditary Tyrosinemia, Type I
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KVD900 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| KVD900 + Placebo to KVD900 | KalVista Pharmaceuticals | Phase 1 | 28 |
| Sebetralstat | KalVista Pharmaceuticals | Pre-clinical | 18 |
| Placebo + KVD900 600 mg + KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 Prototype 1 modified-release tablet + KVD824 Prototype 2 modified-release tablet + KVD824 Immediate-Release Capsule + Placebo to KVD824 Prototype 1 + KVD824 Prototype 3 modified-release tablet | KalVista Pharmaceuticals | Phase 1 | 28 |
| KVD900 150 mg + KVD900 300 mg + KVD900 600 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| KVD824 + Placebo to KVD824 | KalVista Pharmaceuticals | Phase 2 | 47 |
| KVD900 600 mg + Drug: KVD900 300 mg | KalVista Pharmaceuticals | Phase 3 | 72 |
| Deferasirox FCT | Novartis | Phase 2 | 52 |
| Canakinumab + Placebo | Novartis | Phase 3 | 77 |
| Ilaris | Novartis | Pre-clinical | 23 |
| Standard of Care for Haemophilia A | Roche | Pre-clinical | 23 |
| Emicizumab | Roche | Phase 3 | 77 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Pre-clinical | 22 |
| Nitisinone | Swedish Orphan Biovitrum | Phase 1 | 32 |
| Nitisinone | Swedish Orphan Biovitrum | Pre-clinical | 22 |